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Maximising the potential of HPV vaccines
In The Lancet Global Health, Kaja M Abbas and colleagues1 
present revised estimates of the worldwide impact of 
human papillomavirus (HPV) vaccination on prevention 
of cervical cancer, using the Papillomavirus Rapid 
Interface for Modelling and Economics (PRIME) model. 
Their updated analysis uses population demography 
data from the UN World Population Prospects 2019 
revision, disability weights from the Global Burden of 
Disease 2017 study, and cervical cancer burden from 
the Global Cancer Incidence, Mortality and Prevalence 
2018 database.2–4 The revised estimates suggest that the 
potential health impact of HPV vaccines is higher than 
was previously forecast, with health benefits increased 
to 15–19 cases, 12–14 deaths, and 243–306 disability-
adjusted life-years averted per 1000 vaccinated 9-year-
old girls, with the upper and lower limits reflecting the 
estimates for the nonavalent vaccine and bivalent or 
quadrivalent vaccine, respectively.5,6 These increased 
health benefits are assumed to result in improved 
cost-effectiveness of the vaccines—ie, the costs per 
fully immunised girl remain similar, while at the same 
time more cases are averted. The WHO African region 
is estimated to benefit the most from HPV vaccination 
introduction and scale-up. However, this will be a 
challenge in the present situation of HPV vaccine 
scarcity.7 In the context of the report by Abbas and 
colleagues, three issues warrant further consideration: 
potential differences between the vaccines, potential 
reduced vaccination schedules, and prevention of 
cancers other than cervical cancer.
In this study, Abbas and colleagues assume equal 
effectiveness of the bivalent and quadrivalent vaccine 
in targeting two oncogenic types, HPV 16 and 18.1 
Although this assumption holds when considering 
the effectiveness of both vaccines against HPV 16 and 
18, a substantial difference in effectiveness against 
cervical intraepithelial neoplasia grade 3 (CIN3+) 
lesions, irrespective of HPV type, has been noted 
previously. Randomised controlled trials have shown 
that in baseline HPV-negative cohorts, the effectiveness 
against CIN3+, irrespective of HPV type, was 93% for the 
bivalent vaccine and 43% for the quadrivalent vaccine.8 
This trend is also seen in girls routinely vaccinated 
against HPV in Scotland (89% effectivness against 
CIN3+, bivalent vaccine) and Sweden (64%, quadrivalent 
vaccine).9,10 Therefore, the impact of the bivalent 
vaccine might exceed the benefits estimated by Abbas 
and colleagues.1 However, the effectiveness of all HPV 
vaccines is based on surrogate outcomes for cervical 
cancer, because follow-up to assess the vaccines’ impact 
on cervical cancer would span over decades. Over time, 
we will learn how these surrogate outcomes relate to 
cervical cancer and if there are differences between the 
bivalent and quadrivalent vaccine.
In a meeting in October, 2019, the WHO Strategic 
Advisory Group of Experts on Immunization noted 
the shortage of HPV vaccines. The group advised 
potentially pausing implementation of extended 
vaccination strategies for older girls or women and 
boys, and applauded the ongoing research on single-
dose effectiveness.11 Pragmatic analyses of data in two 
clinical trials in which planned doses were missed, as well 
as evaluations in real-world contexts, have shown the 
effectiveness of one-dose schedules. In a white paper 
published by the Single-Dose HPV Vaccine Evaluation 
Consortium (led by PATH), 23 studies are identified in 
a systematic review, most of which found the highest 
effectiveness with three doses, followed by two doses, 
and then one dose.12 Of note, the more recent studies 
with younger vaccines showed small or no differences 
by the number of doses. A single-dose strategy would 
help to alleviate the issues concerning shortages of HPV 
vaccine, and would enhance the potential to introduce 
and scale up vaccination in regions where the burden 
of cervical cancer is highest. Although the evidence for 
the effectiveness of single-dose vaccination is not yet as 
clear as for two or three doses, we could consider taking 
a leap of faith, as was done with the surrogate cervical 
cancer outcomes, to increase the potential of HPV 
vaccines by switching to a single-dose strategy.
This study, and much of the debate around HPV 
vaccination, focuses on cervical cancer. However, 
HPV is known to infect other areas in the anogenital 
tract, including the vagina, vulva, penis, and anus, 
and also areas in the head and neck.8 Globally, the 
annual incidence of non-cervical HPV-related cancers 
is estimated to be 113 000 in both sexes.13 Averting 
these infections and associated cancers by vaccination 
will potentially improve the cost-effectiveness of the 
vaccine, and could even make it cost-saving. Including 
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these non-cervical HPV-related cancers in cost-effective-
ness analyses of HPV vaccines could add an additional 
incentive for introducing HPV vaccination.
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